ESMO 2023: Belzutifan for the treatment of advanced kidney cancer
Treatments for people with metastatic kidney cancer have changed over [...]
Nivolumab plus cabozantinib for advanced non-clear cell kidney cancer
Updated results and further follow up from the CaboNivo study [...]
Promising new anti-cancer treatment for advanced kidney cancer
The results of a study with a new anti-cancer medication [...]
Atezolizumab plus cabozantinib for previously treated metastatic kidney cancer
The results of the CONTACT-03 study with atezolizumab plus cabozantinib [...]
Triple combination for previously untreated advanced non-clear cell kidney cancer
The COSMIC-313 study previously showed improved survival when combining cabozantinib [...]
Cabozantinib plus atezolizumab in non-clear cell kidney cancer
The results from an extended follow-up of the phase 1b [...]
Triple combination improves survival in patients with advanced kidney cancer
Results from the phase 3 COSMIC-313 trial showed that adding [...]
Belzutifan plus cabozantinib combination shows promising results in kidney cancer
Kidney cancers often have mutations in a gene called the [...]
ASCO GU 20023: Cabozantinib as a second-line treatment for patients with advanced kidney cancer
At the American Society of Clinical Oncology Genitourinary Cancers Conference [...]
ASCO GU 2023: A triple combination for previously untreated kidney cancer patients
At the American Society of Clinical Oncology Genitourinary Cancers Conference [...]
